William L. Read

William L. Read

Auto-generated profile, based on publicly available information

William L. Read

Emory University School of Medicine , Atlanta , USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJeffrey M. Switchenko
Jeffrey M. Switchenko
AHArielle L. Heeke
Arielle L. Heeke
TPTony C. Pan
Tony C. Pan
WRWilliam L. Read
William L. Read
Randomized clinical trials compare participants receiving an experimental intervention to participants receiving standard of care (SOC). If one could predict the outcome for participants receiving SOC, a trial could be designed where all participants received the experimental intervention, with the observed outcome of the experimental group compared to the prediction for those individuals. We used the CancerMath calculator to predict outcomes for participants in two large clinical trials of adjuvant chemotherapy for breast cancer: NSABPB15 and CALGB9344. NSABPB15 was the training set, and we used the modified algorithm to predict outcomes for two groups from CALGB9344: one which received standard of care (SOC) chemotherapy and one which received paclitaxel in addition. We made a prediction for each individual CALGB9344 participant, assuming each received only SOC. The predicted outcome for the group which received only SOC matched what was observed in the CALGB9344 trial. In contrast, the predicted outcome for the group also receiving paclitaxel was significantly worse than what was observed for this group. This matches the conclusion of CALGB9344 that adding paclitaxel to SOC improves survival. This project proves that a statistical model can predict the outcome of clinical trial participants treated with SOC. In some circumstances, a predictive model could be used instead of a control arm, allowing all participants to receive experimental treatment. Predictive models for cancer and other diseases could be constructed using the vast amount of outcomes data available to the federal government, and made available for public use.

1 November 2016 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
RSRoger Stupp
Roger Stupp
Ahmed IdbaihAhmed Idbaih
Ahmed Idbaih
DSDavid M. Steinberg
David M. Steinberg
WRWilliam Read
William Read
STSteven Toms
Steven Toms
ZRZvi Ram
Zvi Ram
Tumor Treating Fields (TTFields) is an established, frequency-tuned, anti-mitotic, physical treatment modality that acts in metaphase, anaphase and telophase. TTFields are delivered to the brain by a patient operated, portable medical device (Optune™, Novocure Ltd.). An international, multicenter, prospective, randomized phase 3 trial (EF-14) was initiated in 2009 to test the efficacy and safety of combining TTFields with temozlomide (TMZ) compared to TMZ alone following radiation therapy with adjuvant TMZ in patients with newly diagnosed GBM. Results of a protocol pre-specified successful interim analysis on the first 315 patients randomized has been reported (Stupp et al. JAMA 2015). Here we report the main outcomes of all 695 patients enrolled with a mature minimum follow-up of 18 month (median follow-up 36 months) for all patients (Range 19–80 months). Within 7 weeks after the end of TMZ/RT and stratification for extent of resection and MGMT status patients were randomized (at a 1:2 ratio) to either standard adjuvant TMZ alone (150–200 mg/m2/d x 5d) or TMZ and continuous administration of TTFields. Eligible patients had a newly diagnosed GBM, non-progressive after concomitant chemoradiotherapy, a performance status of ≥70%, and adequate hematological, liver and renal function. The primary endpoint of the study is progression free survival (PFS) as determined by blinded central radiology review; overall survival (OS) is a powered secondary endpoint. A total of 695 patients were randomized from 7/2009 – 11/2014. Patient characteristics are balanced, median age was 56 years (range 19–83), 87 % had undergone prior tumor resection and 13 % a biopsy only. 37% of tumors were MGMT methylated. Median time from end of radiotherapy to randomization was 37 days. The median number of adjuvant (maintenance) TMZ cycles 6 and 5 cycles, for TTFields/TMZ and TMZ alone, respectively. All analyses are intent-to-treat. The median progression-free survival was 6.7 months (95%CI 6.1–8.1) for the patients treated with TTFields/TMZ versus 4.0 months (CI 3.8 – 4.3) for TMZ alone (hazard ratio 0.63, p<0.00005). Median overall survival from randomization is 21 months versus 16 months for the TTFields/TMZ and TMZ alone, respectively, with a hazard ratio of 0.65 (CI 0.54–0.79), p<0.00062. The respective 2, 3 and 4-year survival rates are 43% (CI 38–47%) and 30% (CI 24–37), 24% (CI 19–29) and 16% (CI 11–23), 17% (CI 13–23) and 10% (CI 6–18); p<0.05 for all time points. This first and mature analysis of the full cohort of all randomized patients confirms and improves upon the superior results of TTFields/TMZ compared to TMZ alone seen in the trial’s interim analysis. The addition of TTFields to maintenance TMZ significantly extends both median and long term survival of patients with glioblastoma. The magnitude of survival benefit seen is equivalent to that seen for addition of TMZ to radiation which established TMZ as the standard of care for 1st line glioblastoma over a decade ago.

24 November 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
NSNeeta Somaiah
Neeta Somaiah
Brian Van TineBrian Van Tine
Brian Van Tine
AWAmy E. Wahlquist
Amy E. Wahlquist
MMMohammed M. Milhem
Mohammed M. Milhem
EHElizabeth G. Hill
Elizabeth G. Hill
AKAndrew S. Kraft
Andrew S. Kraft

17 October 2016 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
WRWilliam L. Read
William L. Read
FWFelicia Williams
Felicia Williams
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year. After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib.

12 March 2016 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
WRWilliam L. Read
William L. Read
FWFelicia Williams
Felicia Williams
Kasabach-Merritt syndrome (KMS) describes a consumptive coagulopathy associated with certain vascular tumors. It is thought that platelets are destroyed as they circulate through the aberrant endothelial surfaces associated with these tumors. Most published literature describes infants with kaposiform hemangioendothelioma, but a similar syndrome can complicate angiosarcoma in adults. This report describes a man with metastatic angiosarcoma arising in the scalp in whom disease progression was complicated by profound thrombocytopenia consistent with KMS. His disease and associated KMS had progressed previously through paclitaxel and then through liposomal doxorubicin. It did not respond to paclitaxel and bevacizumab, but responded almost completely to chemotherapy with gemcitabine and vinorelbine. Six months later, progression through ongoing chemotherapy then responded to chemotherapy with cyclophosphamide and sirolimus.

1 May 2015 in JAAD Case Reports
Verified
Journal Article
Open access
WRWilliam L. Read
William L. Read
KBKevin T. Brumund
Kevin T. Brumund
RWRobert A. Weisman
Robert A. Weisman
ANAngel Q. Nguyen
Angel Q. Nguyen